BYSI

BeyondSpring Inc. (BYSI) | Rumor.io

BeyondSpring

BYSI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,373

Bullish sentiment (50-day avg)78%

Price to earnings ratio-56

Market capitalization46.1M

Earnings per share-0.18

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-14.2M

Social

What share of all stock conversation is about BYSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 29

BeyondSpring Inc.'s plinabulin has received FDA Fast Track Designation for post-ICI non-squamous NSCLC, a significant development for the company.
The FDA Fast Track Designation is expected to accelerate the Phase 3 DUBLIN-4 trial, which is being funded in part by a strategic transaction with a Chinese partner.
The company's stock price has surged following the announcement, with some analysts predicting a potential trend to $2-3.

Generated by AI

Sentiment

Of the messages about BYSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +28.36	74.45% -13.05
Bearish	0% 0	0%	0% -28.36	25.55% +13.05

Bullish· Aug 13

BeyondSpring Inc. has the potential to trade above $6 if announcements were made by a Chinese company, indicating its value is tied to its country of origin.
The stock's volume is increasing, suggesting a surge in interest and a possible price increase to $8-10 or $4.75 to break even.
With good news, the stock could experience a significant squeeze, allowing investors to take advantage of high premium through covered calls.

Bearish· Aug 13

BeyondSpring Inc. ($BYSI) has failed to meet expectations, with the stock declining instead of rising.
The company is facing challenges, with one post labeling it a "Chinese scam company" and another describing it as a "bloated pig".
The stock's short sellers have been highly successful, with one post stating that shorts won 98% of the fights.

Generated by AI

Topics

Of the messages about BYSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	75%	31.91%
Announcements	0%	0%	25%	68.09%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Dec 2

Jefferies analyst Maury Raycroft downgraded BeyondSpring from Buy to Hold and lowered the price target from $38 to $5.
B of A Securities analyst Jason Gerberry downgraded BeyondSpring from Buy to Underperform and lowered the price target from $45 to $5.
Evercore ISI lowered the price target for BeyondSpring to $25 from $95, while maintaining an Outperform rating.

Announcements· Apr 14

BeyondSpring's plinabulin treatment more than doubled the objective response rate in a small cell lung cancer trial, with one patient showing exceptional results after 58 cycles.
BeyondSpring Inc. announced its fourth quarter and year-end 2021 financial results, with a net loss of $1.64 per share and revenue of $1.35 million.
BeyondSpring filed its 2021 Annual Report on Form 20-F with the SEC, providing a corporate update and detailing its financial performance for the year.

Technical Analysis· Mar 6

$BYSI is expected to break through resistance at $4 and potentially reach $6 if it holds.
A cup and handle breakout on the 1HR chart and a golden cross on the 16HR chart are indicators of a potential uptrend.
The stock has shown strong relative strength, with a 90-minute and 4HR chart indicating a re-test of the 33EMA and a possible bull-flag formation.

Generated by AI

Community

Of the messages about BYSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	45.45%	16.33%	28.81%	23.03%
Newcomers	54.55%	83.67%	71.19%	76.97%

Regulars· Mar 6

BeyondSpring Inc. has seen a significant surge in trading volume, with some messages noting increases of 2573%, 2401%, and 2269% above average volume.
The company's stock has been experiencing a strong upward trend, with several messages mentioning percentage gains, including a 17.93% increase, a 22.04% increase, and a 23.10% increase.
Some regular participants are discussing the potential for the stock to break through the $4 level and continue to rise, with one message suggesting a target price of $6.

Newcomers· Sep 29

Many newcomers are discussing BeyondSpring Inc.'s (BYSI) recent price surge, with some predicting a potential target price of $1.18.
The FDA has granted Fast Track Designation for BYSI's plinabulin in post-ICI non-squamous NSCLC, which is being seen as a positive development by some analysts.
BYSI's recent volume increase has caught the attention of some traders, with some expecting a potential spike up to $1.15 or $1.20, while others are expressing skepticism about the stock's prospects.

Generated by AI

BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.

21h agoYahoo Finance

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

1d agoYahoo Finance

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of

1mo agoYahoo Finance

12 Health Care Stocks Moving In Thursday's Intraday Session

1mo agoBenzinga

Also Discussed

Investors talking about BYSI also mention

#	Name	Attention
1	CTIC - CTI BioPharma Corp.	——
2	Longeveron Inc. Class A Common StockLGVN	0%0
3	Pasithea Therapeutics Corp.KTTA	0%0
4	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
5	Context Therapeutics Inc.CNTX	0%0
6	Biofrontera Inc.BFRI	0%0
7	Fennec Pharmaceuticals Inc.FENC	0%0
8	Fulcrum Therapeutics, Inc.FULC	0%0
9	ERYP - ERYTECH Pharma S.A.	——
10	Flora Growth Corp.FLGC	0%new

BeyondSpring Inc.

Healthcare
Biotechnology

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.

Website

Location

100 Campus Drive

Florham Park, NJ, 07932

United States

Social

What share of all stock conversation is about BYSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 29

BeyondSpring Inc.'s plinabulin has received FDA Fast Track Designation for post-ICI non-squamous NSCLC, a significant development for the company.
The FDA Fast Track Designation is expected to accelerate the Phase 3 DUBLIN-4 trial, which is being funded in part by a strategic transaction with a Chinese partner.
The company's stock price has surged following the announcement, with some analysts predicting a potential trend to $2-3.

Generated by AI

Sentiment

Of the messages about BYSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +28.36	74.45% -13.05
Bearish	0% 0	0%	0% -28.36	25.55% +13.05

Bullish· Aug 13

BeyondSpring Inc. has the potential to trade above $6 if announcements were made by a Chinese company, indicating its value is tied to its country of origin.
The stock's volume is increasing, suggesting a surge in interest and a possible price increase to $8-10 or $4.75 to break even.
With good news, the stock could experience a significant squeeze, allowing investors to take advantage of high premium through covered calls.

Bearish· Aug 13

BeyondSpring Inc. ($BYSI) has failed to meet expectations, with the stock declining instead of rising.
The company is facing challenges, with one post labeling it a "Chinese scam company" and another describing it as a "bloated pig".
The stock's short sellers have been highly successful, with one post stating that shorts won 98% of the fights.

Generated by AI

Topics

Of the messages about BYSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	75%	31.91%
Announcements	0%	0%	25%	68.09%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Dec 2

Jefferies analyst Maury Raycroft downgraded BeyondSpring from Buy to Hold and lowered the price target from $38 to $5.
B of A Securities analyst Jason Gerberry downgraded BeyondSpring from Buy to Underperform and lowered the price target from $45 to $5.
Evercore ISI lowered the price target for BeyondSpring to $25 from $95, while maintaining an Outperform rating.

Announcements· Apr 14

BeyondSpring's plinabulin treatment more than doubled the objective response rate in a small cell lung cancer trial, with one patient showing exceptional results after 58 cycles.
BeyondSpring Inc. announced its fourth quarter and year-end 2021 financial results, with a net loss of $1.64 per share and revenue of $1.35 million.
BeyondSpring filed its 2021 Annual Report on Form 20-F with the SEC, providing a corporate update and detailing its financial performance for the year.

Technical Analysis· Mar 6

$BYSI is expected to break through resistance at $4 and potentially reach $6 if it holds.
A cup and handle breakout on the 1HR chart and a golden cross on the 16HR chart are indicators of a potential uptrend.
The stock has shown strong relative strength, with a 90-minute and 4HR chart indicating a re-test of the 33EMA and a possible bull-flag formation.

Generated by AI

Community

Of the messages about BYSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	45.45%	16.33%	28.81%	23.03%
Newcomers	54.55%	83.67%	71.19%	76.97%

Regulars· Mar 6

BeyondSpring Inc. has seen a significant surge in trading volume, with some messages noting increases of 2573%, 2401%, and 2269% above average volume.
The company's stock has been experiencing a strong upward trend, with several messages mentioning percentage gains, including a 17.93% increase, a 22.04% increase, and a 23.10% increase.
Some regular participants are discussing the potential for the stock to break through the $4 level and continue to rise, with one message suggesting a target price of $6.

Newcomers· Sep 29

Many newcomers are discussing BeyondSpring Inc.'s (BYSI) recent price surge, with some predicting a potential target price of $1.18.
The FDA has granted Fast Track Designation for BYSI's plinabulin in post-ICI non-squamous NSCLC, which is being seen as a positive development by some analysts.
BYSI's recent volume increase has caught the attention of some traders, with some expecting a potential spike up to $1.15 or $1.20, while others are expressing skepticism about the stock's prospects.

Generated by AI

BeyondSpring

Social

Sep 29

Sentiment

Bullish· Aug 13

Bearish· Aug 13

Topics

Analysts· Dec 2

Announcements· Apr 14

Technical Analysis· Mar 6

Community

Regulars· Mar 6

Newcomers· Sep 29

News

BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Thursday's Intraday Session

Also Discussed

BeyondSpring Inc.

Company Information

Location

Social

Sep 29

Sentiment

Bullish· Aug 13

Bearish· Aug 13

Topics

Analysts· Dec 2

Announcements· Apr 14

Technical Analysis· Mar 6

Community

Regulars· Mar 6

Newcomers· Sep 29

News

BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Thursday's Intraday Session

Also Discussed